These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38923416)

  • 21. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
    Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
    Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
    Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
    Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
    Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.
    Kuwana M; Hasegawa M; Fukue R; Shirai Y; Ishikawa O; Endo H; Ogawa F; Goto D; Kawaguchi Y; Sato S; Ihn H; Takehara K
    Mod Rheumatol; 2021 Mar; 31(2):386-393. PubMed ID: 32552202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.
    Lofgren S; Hinchcliff M; Carns M; Wood T; Aren K; Arroyo E; Cheung P; Kuo A; Valenzuela A; Haemel A; Wolters PJ; Gordon J; Spiera R; Assassi S; Boin F; Chung L; Fiorentino D; Utz PJ; Whitfield ML; Khatri P
    JCI Insight; 2016 Dec; 1(21):e89073. PubMed ID: 28018971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision.
    Correia C; Mawe S; Lofgren S; Marangoni RG; Lee J; Saber R; Aren K; Cheng M; Teaw S; Hoffmann A; Goldberg I; Cowper SE; Khatri P; Hinchcliff M; Mahoney JM
    Arthritis Res Ther; 2020 Mar; 22(1):48. PubMed ID: 32171325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.
    Fernández-Codina A; Nevskaya T; Baron M; Thomas Appleton C; Cecchini MJ; Philip A; El-Shimy M; Vanderhoek L; Pinal-Fernández I; Pope JE
    Rheumatology (Oxford); 2024 Apr; ():. PubMed ID: 38652570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
    Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
    Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
    Wannarong T; Muangchan C
    Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
    Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
    Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
    Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
    Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
    Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
    Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
    Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
    Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
    Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
    Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
    Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.